ATE239792T1 - Ribosomen inaktivierende proteine enthaltende materialien, verfahren zu ihrer herstellung und ihre verwendung - Google Patents

Ribosomen inaktivierende proteine enthaltende materialien, verfahren zu ihrer herstellung und ihre verwendung

Info

Publication number
ATE239792T1
ATE239792T1 AT92924279T AT92924279T ATE239792T1 AT E239792 T1 ATE239792 T1 AT E239792T1 AT 92924279 T AT92924279 T AT 92924279T AT 92924279 T AT92924279 T AT 92924279T AT E239792 T1 ATE239792 T1 AT E239792T1
Authority
AT
Austria
Prior art keywords
rips
vectors
analogs
therapeutic agents
rip
Prior art date
Application number
AT92924279T
Other languages
English (en)
Inventor
Susan L Bernhard
Marc D Better
Stephen F Carroll
Julie A Lane
Shau-Ping Lei
Original Assignee
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Corp filed Critical Xoma Corp
Application granted granted Critical
Publication of ATE239792T1 publication Critical patent/ATE239792T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT92924279T 1991-11-04 1992-11-04 Ribosomen inaktivierende proteine enthaltende materialien, verfahren zu ihrer herstellung und ihre verwendung ATE239792T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78756791A 1991-11-04 1991-11-04
US07/901,707 US5376546A (en) 1991-11-04 1992-06-19 Analogs of ribosome-inactivating proteins
PCT/US1992/009487 WO1993009130A1 (en) 1991-11-04 1992-11-04 Materials comprising and methods of preparation and use for ribosome-inactivating proteins

Publications (1)

Publication Number Publication Date
ATE239792T1 true ATE239792T1 (de) 2003-05-15

Family

ID=27120667

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92924279T ATE239792T1 (de) 1991-11-04 1992-11-04 Ribosomen inaktivierende proteine enthaltende materialien, verfahren zu ihrer herstellung und ihre verwendung

Country Status (7)

Country Link
US (2) US5376546A (de)
EP (2) EP1344826A1 (de)
JP (2) JP3759163B2 (de)
AT (1) ATE239792T1 (de)
CA (1) CA2122714C (de)
DE (1) DE69233045T2 (de)
WO (1) WO1993009130A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4040954C2 (de) * 1990-12-20 2001-05-17 Max Planck Gesellschaft Verfahren zur Erzeugung von pathogen-resistenten Pflanzen
WO1994026910A1 (en) * 1993-05-12 1994-11-24 Xoma Corporation Immunotoxins comprising gelonin and an antibody
US6146850A (en) * 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US7754211B2 (en) * 1992-04-10 2010-07-13 Research Development Foundation Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens
KR960015747B1 (ko) * 1993-07-02 1996-11-20 주식회사 진로 양자리공의 항바이러스성 단백질(pap)을 발현하는 미생물
NO180167C (no) * 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US5973137A (en) * 1996-02-13 1999-10-26 Gentra Systems, Inc. Low pH RNA isolation reagents, method, and kit
US5851802A (en) * 1996-03-22 1998-12-22 Xoma Corporation Methods for recombinant microbial production of fusion proteins and BPI-derived peptides
EP0956051A1 (de) * 1996-09-12 1999-11-17 Genemedicine, Inc. Mittel und verfahren zur verabreichung von genen an die lunge
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
WO1998055623A1 (en) 1997-06-06 1998-12-10 Tanox Pharma B.V. Type-1 ribosome-inactivating protein
US6242219B1 (en) * 1999-03-18 2001-06-05 Xoma (Us) Llc Methods for recombinant peptide production
US20080318889A1 (en) * 1999-04-08 2008-12-25 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US8114850B2 (en) * 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US7960540B2 (en) * 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US20080318890A1 (en) * 1999-04-08 2008-12-25 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
WO2000061597A1 (en) 1999-04-08 2000-10-19 Uab Research Foundation Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin
DE19953517C1 (de) * 1999-11-05 2001-08-09 Medac Klinische Spezialpraep Verwendung von Treosulfan zur Konditionierung von Patienten vor Knochemarktransplantation oder Blutstammzelltransplantation
KR20120053525A (ko) 2000-06-16 2012-05-25 캠브리지 안티바디 테크놀로지 리미티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US6869787B2 (en) * 2002-02-27 2005-03-22 The United States Of America As Represented By The Secretary Of The Army Ricin vaccine and methods of making and using thereof
KR20080074120A (ko) * 2005-10-13 2008-08-12 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US20090131351A1 (en) * 2007-11-16 2009-05-21 Antisoma Research Limited Methods, compositions, and kits for modulating tumor cell proliferation
WO2009108898A2 (en) * 2008-02-27 2009-09-03 Bioo Scientific Corporation Production and uses of type 1 ribosome inactivating proteins
CN101434657B (zh) * 2008-12-03 2011-09-07 山西康宝生物制品股份有限公司 重组mtVEGF121/MAP30KDEL融合毒素的制备与应用
IL314969A (en) * 2022-02-17 2024-10-01 Atb Therapeutics Recombinant immunotoxin comprising a ribosome inactivating protein
CN115645512B (zh) * 2022-09-05 2023-09-01 深圳大学 天花粉蛋白在制备治疗和/或预防银屑病药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2577135B1 (fr) * 1985-02-13 1989-12-15 Sanofi Sa Immunotoxines a longue duree d'action comportant un constituant glycopeptidique inactivant les ribosomes modifie sur ses motifs polysaccharidiques
US4888415A (en) * 1985-03-04 1989-12-19 Dana-Farber Cancer Institute, Inc. Gelonin immunotoxin
JPH0720883B2 (ja) * 1985-03-04 1995-03-08 ダナ−フア−バ− キヤンサ− インステイテユ−ト，インコ−ポレイテツド 免疫毒素及びその製造方法
EP0246307B1 (de) * 1985-11-13 1994-02-02 University Hospital The Durch cys-kodon modifizierte dns
US4853871A (en) * 1987-04-06 1989-08-01 Genex Corporation Computer-based method for designing stablized proteins
GB8801877D0 (en) * 1988-01-28 1988-02-24 Erba Carlo Spa Nucleotide sequence encoding plant ribosome inactivating protein
US5101025A (en) * 1989-04-04 1992-03-31 Genelabs Incorporated Recombinant trichosanthin and coding sequence

Also Published As

Publication number Publication date
US5376546A (en) 1994-12-27
CA2122714A1 (en) 1993-05-13
EP0669982A1 (de) 1995-09-06
EP1344826A1 (de) 2003-09-17
US5416202A (en) 1995-05-16
DE69233045T2 (de) 2004-02-12
DE69233045D1 (de) 2003-06-12
JP2004141153A (ja) 2004-05-20
CA2122714C (en) 2002-08-06
EP0669982B1 (de) 2003-05-07
EP0669982A4 (de) 1995-01-02
JP3759163B2 (ja) 2006-03-22
JPH07504883A (ja) 1995-06-01
WO1993009130A1 (en) 1993-05-13

Similar Documents

Publication Publication Date Title
ATE239792T1 (de) Ribosomen inaktivierende proteine enthaltende materialien, verfahren zu ihrer herstellung und ihre verwendung
ATE236258T1 (de) Gelonin und einen antikörper entahltende immuntoxine
IL150571A0 (en) Novel chimeric proteins and methods for using the same
ATE46718T1 (de) Hybride menschliche leukozyten-interferone, verfahren zu deren mikrobieller herstellung, zwischenverbindungen dafuer und dieselben enthaltende zusammensetzungen.
MX9301700A (es) Muteinas del factor de necrosis tumoral humano, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
EP0595794A4 (de) Klonierte gene, die für elam-1 und für dessen fusionsproteine kodieren sowie die exprimierten proteinprodukte, pharmazeutische zusammensetzungen und deren verwendung.
EP1188830A4 (de) NEUES HäMOPOIETIN REZEPTORPROTEIN NR10
NZ337861A (en) N-heterocyclic derivatives for treating multiple sclerosis, HIV dementia, Parkinson's disease, meningitis, atherosclerosis, cancer, inflammatory skin diseases
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
DE602004001857D1 (de) Thienopyrimidindione und deren verwendung bei der modulierung von autoimmunerkrankungen
NO945034D0 (no) Derivater i vitamin D-serien modifisert ved 20-stilling, en fremg. for frems. av slike derivater, mellomprodukter anvendt ved fremg., farmasöytiske preparater inneholdende derivatene og deres anvendelse ved frems. av legemidler
WO2022256499A3 (en) Bcma targeting trispecific proteins and methods of use
ATE314065T1 (de) Threitol-buttersäureester-enthaltende zusammensetzungen und ihre verwendung
EP1449849A3 (de) Protease-resistentes Thrombomodulinanalog
ES2240971T3 (es) Genes supresores de tumores, proteinas codificadas por ellos y uso de dichos genes y proteinas.
DK0877803T3 (da) OB-proteinreceptor og relaterede sammensætninger og fremgangsmåder
CN1056084C (zh) 抗与表面抗原相关的cd33的免疫毒素
IL108707A0 (en) Vpr function and activity
DE69328060D1 (de) Angiotensin-II Typ-1 Rezeptor und dessen Herstellung
ATE432349T1 (de) Modifizierte hämoglobinähnliche verbindungen und verfahren zu deren reinigung
EP0227809A4 (de) Verfahren und zusammensetzung zur behandlung von krebs und nichtmalignen tumoren.
BRPI0409683A (pt) 5-hidroxiindóis com grupos n-óxido e seu emprego como agentes terapêuticos
Bernhard et al. Materials comprising and methods of preparation and use for ribosome-inactivating proteins
WO2002079222A3 (en) Fusion proteins for specific treatment of cancer and auto-immune diseases
BR9814433A (pt) "beta-lipotropina e usos da mesma"

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties